Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London

Minerva Neurosciences (NERV) management will participate in the 2026 Jefferies Global Healthcare Conference in London on November 16–17, 2026.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Minerva Neurosciences (NERV) management will participate in the 2026 Jefferies Global Healthcare Conference in London on November 16–17, 2026. The format includes a fireside chat on November 16 from 4:00 to 4:25 p.m. GMT and one-on-one meetings. A live webcast will be available through the company website’s events section, with an archived replay available approximately two hours after the event ends.

Key Terms

central nervous system, phase 3 trial

2 terms

central nervous system medical

"development of therapies to treat central nervous system disorders"

The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.

phase 3 trial medical

"conducting a confirmatory Phase 3 trial with roluperidone"

A Phase 3 trial is a large, late-stage test of a new drug or medical treatment done on many people to make sure it really works and is safe. For investors, it matters because a successful Phase 3 usually means the company can ask regulators to sell the product and could earn lots of money, while failure can sharply reduce the company’s value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

10/29/2026 - 07:00 AM EDT

BURLINGTON, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in the 2026 Jefferies Global Healthcare Conference in London.

2026 Jefferies Global Healthcare Conference
Dates: Monday, November 16 & Tuesday, November 17, 2026
Format: Fireside chat and 1x1 meetings
Fireside Chat: Monday, November 16, 2026 from 4:00 – 4:25 p.m. GMT
Location: London, UK

If you are interested in meeting with the Minerva team during the conference, please reach out to your respective Jefferies representative.

The live webcast can be accessed in the events section of the Minerva Neurosciences website HERE. Access to the webcast replay will be available approximately two hours after the completion of the event and will be archived on the Company’s website.

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is conducting a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’s website.

Contacts:
Frederick Ahlholm
Chief Financial Officer
Minerva Neurosciences, Inc.
FAhlholm@minervaneurosciences.com

Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com